[Efficacy and safety of fourth-generation CD19 CAR-T expressing IL7 and CCL19 along with PD-1 monoclonal antibody for relapsed or refractory large B-cell lymphoma].

MLA

Yu, T., et al. “[Efficacy and Safety of Fourth-Generation CD19 CAR-T Expressing IL7 and CCL19 along with PD-1 Monoclonal Antibody for Relapsed or Refractory Large B-Cell Lymphoma].” Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, vol. 44, no. 10, Oct. 2023, pp. 820–24. EBSCOhost, https://doi.org/10.3760/cma.j.issn.0253-2727.2023.10.005.

APA

Yu, T., Liu, H., Lei, W., Chen, P. P., Zhao, A. Q., Yuan, X. G., Gao, J. M., & Qian, W. B. (2023). [Efficacy and safety of fourth-generation CD19 CAR-T expressing IL7 and CCL19 along with PD-1 monoclonal antibody for relapsed or refractory large B-cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 44(10), 820–824. https://doi.org/10.3760/cma.j.issn.0253-2727.2023.10.005

Chicago

Yu, T, H Liu, W Lei, P P Chen, A Q Zhao, X G Yuan, J M Gao, and W B Qian. 2023. “[Efficacy and Safety of Fourth-Generation CD19 CAR-T Expressing IL7 and CCL19 along with PD-1 Monoclonal Antibody for Relapsed or Refractory Large B-Cell Lymphoma].” Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi 44 (10): 820–24. doi:10.3760/cma.j.issn.0253-2727.2023.10.005.